anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An application running on a device to manage insulin site rotation may read a configuration file including a group, a plurality of sites in the group, and an image associated with the group. The application may detect an input selecting a site from the plurality of sites for administration of an insulin management device. The application may also set the selected site as unavailable for a predetermined duration in response to the input selecting the site. A log entry may be written to track usage of the site in response to the input selecting the site. A visual indicator on the selected site may show that the site is recently selected in response to detecting the input selecting the site within a predetermined duration. The insulin management device may be a pump, a syringe, or a glucose monitor.
FIELD: medicine. SUBSTANCE: essence of new method resides in treating peripheral blood of Cervus nippon. This method prescribes collecting peripheral blood during period of peak physiological activity and cutting of non-ossified velvet antlers and then admixing it with auxiliary compounds. Object of invention is reinforcement of specific activity and diminishing of side effect. EFFECT: speedy restoration of quantitative and qualitative ratios of formed elements of blood and reduced rate of complications. 4 tbl
A reversibly gated effector polypeptide e.g. a chimeric antigen receptor (protease-activating CD45-gate CAR) comprising an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. Nucleic acids including vectors and expression vectors that encode the protease-activating CD45-gate CAR and cells including immune cells such as T cells that comprise and express the nucleic acids. Methods of treatment of various conditions including various forms of cancer comprising administering the cells including CAR T cell therapy. In some embodiments, the CD45 gate at least partially inhibits activation of the protease-activating CD45-gate CAR when the protease-activating CD45-gate CAR binds antigen. The inhibition is at least partially diminished, relieved and/or eliminated when the protease-activating CD45-gate CAR is exposed to a protease that can cleave the linker.
In the present invention, Melia azedarach L. or Lobelia chinensis Lour. is conventionally used as a herb medicine and medicinal plants in oriental medicine, is a plant containing a variety of physiologically active material, and has not been previously reported to have an anti-tuberculous effect against tuberculous. In the present invention, it was verified that extracts of the Melia azedarach L. or Lobelia chinensis Lour. and fractions thereof have an anti-tuberculous effect and the materials can be used as a composition for treating, alleviating, and preventing tuberculous. The present invention relates to a pharmaceutical composition, a functional health food composition, a feed composition, an animal medicine composition, and a quasi-drug composition, which contain, as an active ingredient, extracts of the Melia azedarach L. or Lobelia chinensis Lour. and fractions thereof for treating, alleviating, and preventing tuberculous. The pharmaceutical composition, functional health food composition, feed composition, animal medicine composition, and quasi-drug composition according to the present invention has an anti-tuberculous effect against tuberculous, and thus can be used as an antibacterial composition for treating, alleviating, and preventing tuberculous.
Sepsis is a life-threatening syndrome of organ dysfunction, characterized by uncontrolled inflammatory response and immune dysregulation, often leading to multiple organ failure and even death. Specialized pro-resolving mediators (SPMs), which are typically thought to be formed via consecutive steps of oxidation of polyenoic fatty acids, have been shown to suppress inflammation and promote timely resolution of inflammation. They are mainly divided into four categories: lipoxins, resolvins, protectins, and maresins. The SPMs may improve the prognosis of sepsis by modulating the immune and inflammatory balance, thereby holding promise for clinical applications. However, their biosynthetic and pharmacological properties are very complex. Through a literature review, we aim to comprehensively elucidate the protective mechanisms of different SPMs in sepsis and its organ damage, in order to provide sufficient theoretical basis for the future clinical translation of SPMs.
(see boxed WARNINGS) 

Additional manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching and convulsions.

The risk of hearing loss continues after drug withdrawal.

Aminoglycosides can cause fetal harm when administered to a pregnant woman. Aminoglycoside antibiotics cross the placenta and there have been several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy. Although serious side effects to fetus or newborn have not been reported in the treatment of pregnant women with other aminoglycosides, the potential for harm exists. Animal reproduction studies of neomycin have not been conducted. If neomycin is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
The invention provides an analgesic and anti inflammatory medicine. The preparation raw materials comprise the components of aloe extracts, berberine, menthol and so on. The invention at the same time provides a preparation method and an application of the analgesic and anti inflammatory medicine. The medicine combination contains the components of aloe, berberine, menthol and so on, which takes full advantage of the medicinal characteristics of each component. The reasonable coordination makes the medicine have the comprehensive therapeutic effect. The experiment shows that the medicine has manifest analgesic effect for hemorrhoid after being processed operation. The medicine is convenient to be used. The use time and the use length can be adjusted on occasion. The medicine also has anti inflammatory effect and can improve wound healing. An ideal medicine is provided for being matched with hemorrhoids and surgical treatment.
BACKGROUND: Spondyloepimetaphyseal dysplasia with joint laxity type 3 (SEMDJL3) is a rare skeletal dysplasia associated with EXOC6B, a component of the exocyst complex, involved in vesicle tethering and exocytosis at the plasma membrane. So far, EXOC6B and the pathomechanisms underlying SEMDJL3 remain obscure.
METHODS AND RESULTS: Exoc6b was detected largely at the perinuclear regions and the primary cilia base in ATDC5 prechondrocytes. Its shRNA lentiviral knockdown impeded primary ciliogenesis. In Exoc6b silenced prechondrocytes, Hedgehog signaling was attenuated, including when stimulated with Smoothened agonist. Exoc6b knockdown deregulated the mRNA and protein levels of Col2a1, a marker of chondrocyte proliferation at 7- and 14-days following differentiation. It led to the upregulation of Ihh another marker of proliferative chondrocytes. The levels of Col10a1, a marker of chondrocyte hypertrophy was enhanced at 14 days of differentiation. Congruently, Axin2, a canonical Wnt pathway modulator that inhibits chondrocyte hypertrophy was repressed. The expression of Mmp13 and Adamts4 that are terminal chondrocyte hypertrophy markers involved in extracellular matrix (ECM) remodelling were downregulated at 7 and 14 days of chondrogenesis. Bglap that encodes for the most abundant non-collagenous bone matrix constituent and promotes ECM calcification was suppressed at 14 days of chondrocyte differentiation. ECM mineralization was assessed by Alizarin Red staining. Gene expression and ciliogenesis were investigated by reverse transcription quantitative real-time PCR, immunoblotting, and immunocytochemistry.
CONCLUSIONS: These findings provide initial insights into the potential role of Exoc6b in primary ciliogenesis and chondrogenic differentiation, contributing towards a preliminary understanding of the molecular pathomechanisms underlying SEMDJL3.
OBJECTIVE: Postoperative thrombotic complications represent a unique challenge in cranial neurosurgery as primary treatment involves therapeutic anticoagulation. The decision to initiate therapy and its timing is nuanced, as surgeons must balance the risk of catastrophic intracranial hemorrhage (ICH). With limited existing evidence to guide management, current practice patterns are subjective and inconsistent. The authors assessed their experience with early therapeutic anticoagulation (≤ 7 days postoperatively) initiation for thrombotic complications in neurosurgical patients undergoing cranial surgery to better understand the risks of catastrophic ICH.
METHODS: Adult patients treated with early therapeutic anticoagulation following cranial surgery were considered. Anticoagulation indications were restricted to thrombotic or thromboembolic complications. Records were retrospectively reviewed for demographics, surgical details, and anticoagulation therapy start. The primary outcome was the incidence of catastrophic ICH, defined as ICH resulting in reoperation or death within 30 days of anticoagulation initiation. As a secondary outcome, post-anticoagulation cranial imaging was reviewed for new or worsening acute blood products. Fisher's exact and Wilcoxon rank-sum tests were used to compare cohorts. Cumulative outcome analyses were performed for primary and secondary outcomes according to anticoagulation start time.
RESULTS: Seventy-one patients satisfied the inclusion criteria. Anticoagulation commenced on mean postoperative day (POD) 4.3 (SD 2.2). Catastrophic ICH was observed in 7 patients (9.9%) and was associated with earlier anticoagulation initiation (p = 0.02). Of patients with catastrophic ICH, 6 (85.7%) had intra-axial exploration during their index surgery. Patients with intra-axial exploration were more likely to experience a catastrophic ICH postoperatively compared to those with extra-axial exploration alone (OR 8.5, p = 0.04). Of the 58 patients with postoperative imaging, 15 (25.9%) experienced new or worsening blood products. Catastrophic ICH was 9 times more likely with anticoagulation initiation within 48 hours of surgery (OR 8.9, p = 0.01). The cumulative catastrophic ICH risk decreased with delay in initiation of anticoagulation, from 21.1% on POD 2 to 9.9% on POD 7. Concurrent antiplatelet medication was not associated with either outcome measure.
CONCLUSIONS: The incidence of catastrophic ICH was significantly increased when anticoagulation was initiated within 48 hours of cranial surgery. Patients undergoing intra-axial exploration during their index surgery were at higher risk of a catastrophic ICH.
FIELD: medicine, gynecology. SUBSTANCE: the innovation could be applied in preventing inflammatory complications after artificial interruption of pregnancy in trimester I. Intravenous injection of ozonized physiological solution is carried out at the day of operation and a week after artificial interruption of pregnancy. The method enables to prevent the development of infectious complications. EFFECT: higher efficiency of prophylaxis. 3 ex
Polycystic ovary syndrome is a disorder which is associated with insulin resistance, diabetes, obesity, and cardiovascular disease. Endothelial dysfunction, which is known to be an early marker of atherosclerosis, has also been shown to have an association with poycystic ovary syndrome. In this study the investigators aimed to investigate whether there is a relation between polycystic ovary syndrome and serum endocan levels. For this purpose the investigators designed a prospective study including two groups. The diagnosis of polycystic ovary syndrome was made in the presence of ;oligo- and/or anovulation,clinical hyperandrogenism and polycystic ovaries. Clinical hyperandrogenism was defined by the presence of hirsutism , acne, or the presence of androgenic alopecia, body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. The two groups are compared considering their serum endocan levels,follicle stimulating hormone (FSH), luteinizing hormone (LH), Dihydroepiandesterone sulphate (DHEAS), total testesterone (TT), estradiol (E2) and thyroid stimulating hormone (TSH), fasting blood glucose, triglyceride, total cholesterol, high density lipoprotein, low density lipoprotein, and C-reactive protein (CRP) levels.
The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucose and galactose content. The glucose and galactose results are used to directly quantify saccharides from serogroups Y  and W135, respectively, and the combined glucose and galactose content is subtracted from the sialic acid content to quantify saccharides from serogroup C. The three serogroups can thus be resolved even though their monosaccharide contents overlap. The three different monosaccharide analyses can be performed on the same material , without interference between the monosaccharides and without interference from any other saccharide materials in the composition (e.g. lyophilisation stabilisers). The method can be used to analyse total and free saccharide in conjugate vaccines and simplifies quality control of vaccines containing capsular saccharides from multiple serogroups.
PURPOSE: A cosmetic composition and a cosmetic product using the same are provided to check pH condition of the cosmetic product and to confirm acidity of the cosmetic product. CONSTITUTION: A cosmetic composition contains 80-91 weight% of first agent containing anthocyan-containing coloring agent and 9-20 weight% of second agent containing organic acid. The coloring agent is contained in 1-10 weight% and is bilberry extracts. The organic acid is contained in 0.05-2.0 weight%. The organic acid is citric acid, fumaric acid, succinic acid, adipic acid, aspartic acid, or glutamic acid. A cosmetic product containing the composition is manufactured in the form of cream, skin, gel, lotion, pack, cleansing cream, cleansing cream, essence oil, serum, cleansing gel, or sun screen cream.
PURPOSE:An anticandida fungus antibody, obtained by collecting an antibody secreted from a hybridoma of a cell capable of producing the anticandida microorganism antibody and a cell capable of in vitro subculture for a long term, and having improved specificity and high potency with little impurities. CONSTITUTION:An cell capable of producing an anticandida fungus antibody, e.g. a splenic cell, is subjected to the cell fusion with a cell capable of in vitro subculture for a long term, e.g. a strain cell deficient in hypoxanthine-guanine phosphoribosyltransferase, in a solution containing 30-55% fusion accelerator, e.g. Sendai virus or polyethylene glycol, and the resultant fused cell is then cultivated in a culture medium containing hypoxanthine, aminopterin and thymidine to give a hybridoma, which is then transplanted to a living body and multiplied in a solid or ascitic culture medium. Blood serum or ascites are then collected from the living body and purified to afford the aimed anticandida fungus antibody.
PCT No. PCT/FI95/00167 Sec. 371 Date Mar. 15, 1996 Sec. 102(e) Date Mar. 15, 1996 PCT Filed Mar. 29, 1995 PCT Pub. No. WO95/26712 PCT Pub. Date Oct. 12, 1995The present invention is directed to an ophthalmic composition in the form of a topical aqueous solution consisting essentially of an ophthalmologically active agent containing basic groups, an ion sensitive, hydrophilic polymer containing acidic groups in an amount of 0.004 to 1.5% by weight, at least one salt selected from the group of inorganic salts and buffers in a total amount of from 0.01 to 2.0% by weight, and optionally a wetting agent and a preservative, the ratio between salt and polymer being such that the solution exhibits a viscosity of less than 1000 mpas, and the pH of the solution is 4.0 to 8.0. The composition contains a sufficient amount of polymer to provide for a controlled absorption of the drug into the eye, its viscosity having been reduced to provide for better handling characteristics.
Using one of the 5-HT3 receptor antagonists (a. Palonosetron: 0.25 mg d1 intravenous; b. Granisetron: 1 mg d1 intravenously, or 2 mg d1 orally; c. Ondansetron: 8-16 mg d1 intravenous or oral. the specific agent is chosen by the primary clinician, and is only delivered on the first day) within 30 minutes before cisplatin. Using one of the NK-1 receptor antagonists(a. Aprepitant: 125 mg orally, d1, 80 mg orally, d2-3; b. Fosaprepitant: 150 mg intravenously, d1) within 1 hour before cisplatin. On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
PURPOSE:To obtain powder containing alpha-amylase which is stable for a long time when added to an agent having a drude crug, by blending an aqueous solution of bacterium alpha-amylase and gelatin with an organic solvent to give precipitate, followed by drying and grinding the prepared precipitate. CONSTITUTION:An aqueous solution comprising bacterium alpha-amylase and gelatin having a molecular weight of >=5,000 and/or its hydrolyzate is blended with an organic solvent and precipitated at a pH of 6.0-6.8. Ethyl alcohol, etc. may be cited as the organic solvent. The prepared precipitate is dried, and crushed to give powder containing bacterium alpha-amylase. Even if the prepared powder is blended with an agent having a crude drug such as powdered cinnamon bark, powdered clove, etc., it can be preserved for a long time without being influenced by the crude drug component.
NEW MATERIAL:A compound expressed by formula I (R is H or amino- protecting group). EXAMPLE:2-(tert-Butoxycarbonylamino)-2-carboxyethyl (trans-1-propenyl) disulfide. USE:An antitumor agent and intermediate therefor. PREPARATION:A trans-1-propenethiol derivative expressed by formula II (A is thiol eliminative with a halogenating agent) is reacted with an L-cysteine derivative expressed by formula III in the presence of the halogenating agent to afford the compound expressed by formula I. The reaction is carried out by using the compound expressed by formula II and the compound expressed by formula III in an amount of normally about 0.5-1.5 equiv. based on the compound expressed by formula II in the presence of an inert solvent, such as THF, dioxan, methylene chloride or chloroform, and the halogenating agent, such as halogen, such as Cl, Br or I.
Provided are enriched tissue extracts and methods of making and using such extracts. The enriched tissue extracts contain biologically active components. Some extracts produced by the methods contain extracellular vesicles. The methods can involve administering a physical stress on a biological sample comprising live cells or otherwise stimulating the live cells of the biological sample. Also contemplated are methods in which the biological sample does not contain live cells. The biological sample is incubated in an extraction solution for a period of time sufficient for extraction of biologically active components from the biological sample. Methods of using the extracts, or extracellular vesicles isolated therefrom, therapeutically and for in vitro purposes are also provided.
Oral hygiene compositions including pharmacologically active ingredients extracted from one or more species of plants (or interbred strains thereof) in the Cannabis genus. In an embodiment, an extraction process may include techniques to maximize the ratio of tetrahydrocannabinolic acid (“THCA”) to tetrahydrocannabinaol (THC) in the essential oil extract, in order to maximize the presence of the non-euphoric THCA. In an embodiment, a mouthwash composition is provided. In an embodiment, an essential oil extract may be applied neat. In an embodiment, an essential oil extract may be mixed with food grade carriers (e.g. glycerol, or vegetable oil) and/or diluents (e.g. water, ethanol), and used as mouth rinse, in a conventional rinse and spit fashion. In an embodiment, an essential oil extract may be mixed with food grade carries and/or diluents and used as an ingestible composition, in a rise and swallow fashion.
A taste-masked microcapsule composition for administration of a drug is disclosed. The composition comprises microcapsules of drug and a substantially water-insoluble polymeric material, consisting essentially of one or more polymers selected from the group consisting of ethyl cellulose, cellulose acetate phthalate, cellulose acetate butyrate, polymethacrylates, hydroxypropxl methyl cellulose phthalate; carboxymethyl ethylcellulose; polylactic acid and combinations thereof, the polymeric material constituting approximately 30 wt. % to 65 wt. % of the composition.  The microcapsule composition may be incorporated into any number of pharmaceutical formulations, including chewable tablets, effervescent tablets, powders, liquid dispersions, and the like. A method for masking the taste of drugs is also provided, involving a phase separation coacervation technique in which drug is coated with relatively high levels of a polymeric material. These high coating levels give rise to effective taste masking, while nevertheless allowing targeted release of drug, so that the drug is released shortly after passage through the mouth.
Patients receive everolimus PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Lean subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate. The effects of an acute fatty acid infusion on vascular function will be measured on both occasions.
Iron: Signs and Symptoms: Iron is toxic. Acute overdosage of iron may cause nausea and vomiting and, in severe cases, cardiovascular collapse and death. Othersymptoms include pallor and cyanosis, melena, shock, drowsiness and coma. The estimated overdose of orally ingested iron is 300 mg/kg body weight. Whenoverdoses are ingested by children, severe reactions, including fatalities, have resulted. Davimet™ with Iron Multivitamin Chewable Tablets should be stored beyond the reach of children to prevent against accidental iron poisoning.
Propolis exhibits significant anti-inflammatory, antidiabetic, and antiobesity properties in both mouse models and clinical applications. However, the underlying metabolic mechanisms remain poorly understood. Traditional metabolomic methods that rely on chromatographic separation require complex preprocessing steps and extended detection periods. In this study, we employed extraction electrospray ionization mass spectrometry combined with multivariate analysis to directly profile metabolites in the colon tissue of mice. Our findings demonstrate the efficacy of ethanol extract of propolis (EEP) in mitigating weight gain, reducing inflammatory cytokines, and improving insulin resistance induced by a high-fat diet. Additionally, EEP enhanced glucose tolerance. Through collision-induced dissociation experiments, we identified 26 metabolites, with 4-hydroxyphenylacetic acid, protocatechuic acid, caffeic acid, ferulic acid, hippuric acid, histidine, and tryptophan emerging as potential biomarkers. Notably, tryptophan exhibited the highest content at 8.25 mg/g. Our research facilitates rapid profiling of colon metabolites, underscoring its significant potential for broader applications in animal metabolomic studies.
Women in the control group will receive follow-up as in normal routine with referral to primary care. They will receive an OGTT after 1 year as part of the trial.